Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.

@article{Monopoli1998CardiovascularPO,
  title={Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.},
  author={Angela Monopoli and Chiara Casati and Gianluca Lozza and Angelo Forlani and Ennio Ongini},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1998},
  volume={285 1},
  pages={9-15}
}
We characterized the in vivo cardiovascular profile of SCH 58261, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2, 4-triazolo[1,5-c] pyrimidine, a selective A2A adenosine receptor antagonist, in conscious, freely moving rats by use of the telemetry system. In normotensive rats, SCH 58261, at 10 mg/kg i.p., significantly (P < .05) inhibited hypotension and tachycardia induced by the A2A receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine (0.01 mg/kg i.p.), but not the… CONTINUE READING